 | • レポートコード：MRC2303M096 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、126ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料によると、世界の爪真菌症治療市場規模が、2021年までに2,859.7百万ドルとなり、予測期間中に年平均成長率5.75%で拡大し、3,739.31百万ドルに達すると予測されています。本書は、爪真菌症治療の世界市場にフォーカスし、最新動向と今後の市場性などをまとめており、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療別（治療薬、レーザー治療、光線力学療法）分析、種類別（遠位爪甲下型、表在性白色型、近位爪甲下型）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などが掲載されています。また、Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)、Galderma SA、Novartis AG、Pfizer Inc.、Moberg Pharma AB、Johnson & Johnson、Bayer AG、Dr. Reddys Laboratories Ltd、Cipla Ltd、Lumenis Ltd、Medimetriks Pharmaceuticals Inc.など、主要企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の爪真菌症治療市場規模：治療別 - 治療薬における市場規模 - レーザー治療における市場規模 - 光線力学療法における市場規模 ・世界の爪真菌症治療市場規模：種類別 - 遠位爪甲下型爪真菌症治療の市場規模 - 表在性白色型爪真菌症治療の市場規模 - 近位爪甲下型爪真菌症治療の市場規模 ・世界の爪真菌症治療市場規模：地域別 - 北米の爪真菌症治療市場規模 アメリカの爪真菌症治療市場規模 カナダの爪真菌症治療市場規模 メキシコの爪真菌症治療市場規模 … - ヨーロッパの爪真菌症治療市場規模 イギリスの爪真菌症治療市場規模 フランスの爪真菌症治療市場規模 ドイツの爪真菌症治療市場規模 … - アジア太平洋の爪真菌症治療市場規模 中国の爪真菌症治療市場規模 インドの爪真菌症治療市場規模 日本の爪真菌症治療市場規模 … - 南米/中東の爪真菌症治療市場規模 ブラジルの爪真菌症治療市場規模 アルゼンチンの爪真菌症治療市場規模 南アフリカの爪真菌症治療市場規模 … - その他地域の爪真菌症治療市場規模 ・競争状況 ・市場機会・将来の動向 |
The onychomycosis market was estimated to be valued at USD 2859.75 million in 2021 and is expected to reach approximately USD 3739.31 million in 2027, registering a CAGR of nearly 5.75% during the forecast period.
Clinical examination, dermoscopy, and mycological examination were recommended for all patients with suspected onychomycosis prior to the COVID-19 pandemic. Non-urgent in-patient visits are being postponed as the COVID-19 pandemic spreads, and telemedicine may be used to handle some elements of onychomycosis diagnosis and treatment. Telemedicine can be used to assess individuals with suspected onychomycosis, although it’s best for those who have already had their mycological confirmation. As a result, the COVID-19 pandemic is projected to cause a short-term interruption in the market. However, the revenue growth rate is predicted to recover during the forecast period, and the global onychomycosis market is expected to increase at a double-digit rate.
Onychomycosis traditionally referred to a non-dermatophytic infection of the nail but is now used as a general term to denote any fungal nail infection (tinea unguium specifically describes a dermatophytic invasion of the nail plate). Onychomycosis is of different types, such as superficial onychomycosis, distal and lateral subungual onychomycosis, proximal subungual onychomycosis, endonyx onychomycosis, and total dystrophic onychomycosis. Only around half of nail dystrophies are caused by a fungus; hence onychomycosis accounts for one-third of fungal skin infections.
The increasing geriatric population, rising prevalence of onychomycosis, diabetic population worldwide, and growing awareness about the potential threats of onychomycosis are the key driving factors in the onychomycosis treatment market. According to an article titled, ‘High prevalence of mixed infections in global onychomycosis,’ published in 2020, onychomycosis is estimated to occur at a prevalence of 10% worldwide, with the infecting organism most commonly being Trichophyton rubrum. In addition, according to World Health Organization’s (WHO) data in 2021, by 2030, one out of every six persons on the globe will be aged 60 years or older. The number of people aged 60 years and more is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. By 2050, the global population of adults aged 60 years and above will have doubled (2.1 billion).
Onychomycosis Treatment Market Trends
The Drugs Segment is Expected to Hold a Major Share in the Onychomycosis Treatment Market
Some of the drugs available for the treatment of onychomycosis are terbinafine, ciclopirox, Jublia, Fluconazole, Penlac, ciclodan, ketoconazole, Sporanox, Itraconazole, Kerydin, efinaconazole, griseofulvin, and so on. For onychomycosis treatment, drugs remain the first-line treatment choice and hold a major market share owing to a consistently high success rate.
Elewski and Charif’s onychomycosis report states that approximately 40% of the elderly population have onychomycosis and a reduction in nail growth rate ranges from about 40% to 60% in persons aged above 65 years. Furthermore, onychomycosis affects approximately 2% to 26% of different populations globally. However, less than 30% of individuals infected with onychomycosis seek medical advice or treatment in developed countries.
The drugs segment holds a significant share in the onychomycosis treatment market. It is anticipated to show a similar trend over the forecast period due to the products’ highly effective nature and easy availability. In July 2021, Lupin received approval to launch Tavaborole Topical Solution 5% in the US from the US Food and Drug Administration (FDA).
Due to the COVID-19 pandemic, the distribution of drugs was disrupted worldwide due to the supply chain disruptions and was expected to have an impact in 2020. However, in late 2020, 2021, and further years, the onychomycosis market was expected to recover and even show positive growth over the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America is expected to hold a major share in the global onychomycosis treatment market due to high drug costs, rising geriatric population, and increasing prevalence of onychomycosis and diabetic patient populations in this region. According to the Census Bureau’s 2020 population estimates, more than 55 million Americans are aged 65 years or older, of which one-fourth live in one of three states, namely, California, Florida, and Texas. Seven other states, including Georgia, Illinois, Michigan, New York, account for roughly another quarter of the 65+ population.
The reasons for the age-related increase in onychomycosis include a variety of factors, like repeated nail trauma, poor peripheral circulation, diabetes, suboptimal immune function, longer exposure to pathogenic fungi, inactivity, or the inability to cut toenails or maintain good foot care. Various strategies, such as research and development, mergers and acquisitions, and product launches, are being adopted by domestic companies to strengthen their market position.
In October 2020, US-headquartered Pfizer Inc. announced that it had begun clinical studies concerning onychomycosis. The first one involved a study determining whether the AN2690 topical solution is an effective treatment for onychomycosis of the toenail. The second one was an open-label study to evaluate the safety and pharmacokinetics of the tavaborole 5% topical solution to treat distal subungual onychomycosis of the toenail in both children and adolescents.
On the other hand, the COVID-19 pandemic has resulted in decreased diagnosis and impacted the sales revenue of drugs and other treatment methods for onychomycosis as hospitals and primary care centers shifted their focus to COVID-19 patients.
Onychomycosis Treatment Market Competitor Analysis
The onychomycosis treatment market is fragmented and competitive and consists of several major players. Companies are focusing on developments, collaborations, and product launches to strengthen their market position. For instance, in April 2020, the US Food and Drug Administration expanded the approval of Jublia manufactured by Bausch Health. Jublia is a topical solution used to treat onychomycosis in the toenail(s) in patients aged six years and above.
Some of the players currently dominating the market are Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), Galderma SA, Novartis AG, Pfizer Inc., Moberg Pharma AB, Johnson & Johnson, Bayer AG, Dr. Reddy’s Laboratories Ltd, Cipla Ltd, Medimetriks Pharmaceuticals Inc., and Lumenis Ltd.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Onychomycosis Globally
4.2.2 Growing Awareness on the Potential Threats of Onychomycosis
4.3 Market Restraints
4.3.1 Side Effects Associated with Onychomycosis Treatment Drugs
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Treatment Type
5.1.1 Drugs
5.1.2 Laser Therapy
5.1.3 Photodynamic Therapy
5.2 By Type
5.2.1 Distal Subungual Onychomycosis
5.2.2 White Superficial Onychomycosis
5.2.3 Proximal Subungual Onychomycosis
5.2.4 Other Types
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)
6.1.2 Galderma SA
6.1.3 Novartis AG
6.1.4 Pfizer Inc.
6.1.5 Moberg Pharma AB
6.1.6 Johnson & Johnson
6.1.7 Bayer AG
6.1.8 Dr. Reddys Laboratories Ltd
6.1.9 Cipla Ltd
6.1.10 Lumenis Ltd
6.1.11 Medimetriks Pharmaceuticals Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
